US 12,459,910 B2
Mitochondrial therapeutic agents
Omar Khdour, Phoenix, AZ (US); Sidney Hecht, Phoenix, AZ (US); Jun Liu, Scottsdale, AZ (US); and Indrajit Bandyopadhyay, Tempe, AZ (US)
Assigned to ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, Scottsdale, AZ (US)
Appl. No. 18/691,696
Filed by ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, Scottsdale, AZ (US)
PCT Filed Sep. 14, 2021, PCT No. PCT/US2021/050306
§ 371(c)(1), (2) Date Mar. 13, 2024,
PCT Pub. No. WO2023/043432, PCT Pub. Date Mar. 23, 2023.
Prior Publication US 2024/0409521 A1, Dec. 12, 2024
Int. Cl. C07D 279/20 (2006.01); A61K 31/5415 (2006.01)
CPC C07D 279/20 (2013.01) [A61K 31/5415 (2013.01)] 20 Claims
 
1. A compound of formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein: R1 is C2-C20 alkyl optionally substituted with one or more halo.